Natera: Natera and MyOme Announce Launch of iPRS for Breast Cancer Risk Assessment

Natera, Inc. and MyOme announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera's Empower hereditary cancer test the opportunity for further risk assessment using MyOme's integrated polygenic risk score. The launch is supported by a validation study published in JCO Precision Oncology1 of over 130,000 women, which demonstrated that MyOme's cross-ancestry, integrated polygenic risk score significantly improved breast cancer risk prediction over the common clinical measurement, Tyrer-Cuzick (T-C) alone. In the study, up to 8% of women had their T-C lifetime risk of breast cancer reclassified with iPRS, allowing for more informed cancer risk management decisions. Polygenic risk scores account for the combined impact of different variants in an individual's genome rather than those in just a single gene. Early detection and treatment are crucial for improving outcomes. iPRS can provide a more personalized risk assessment for the up to 95% of women who do not have a known pathogenic variant associated with breast cancer.3 By identifying individuals at higher risk, healthcare providers can implement proactive screening, including annual breast MRIs and earlier or more frequent mammograms. iPRS is available to patients between 18 and 85 years of age who have no personal history of breast cancer and no mutations in a breast cancer-related gene.